IN2014DN07956A - - Google Patents
Info
- Publication number
- IN2014DN07956A IN2014DN07956A IN7956DEN2014A IN2014DN07956A IN 2014DN07956 A IN2014DN07956 A IN 2014DN07956A IN 7956DEN2014 A IN7956DEN2014 A IN 7956DEN2014A IN 2014DN07956 A IN2014DN07956 A IN 2014DN07956A
- Authority
- IN
- India
- Prior art keywords
- physiologically active
- constant region
- immunoglobulin constant
- complex
- active polypeptide
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 abstract 3
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 125000001151 peptidyl group Chemical group 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120024136 | 2012-03-08 | ||
PCT/KR2013/001885 WO2013133659A1 (en) | 2012-03-08 | 2013-03-08 | An improved process for preparation of physiologically active polypeptide complex |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN07956A true IN2014DN07956A (ja) | 2015-05-01 |
Family
ID=49117067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN7956DEN2014 IN2014DN07956A (ja) | 2012-03-08 | 2013-03-08 |
Country Status (18)
Country | Link |
---|---|
US (1) | US11168109B2 (ja) |
EP (1) | EP2822972A4 (ja) |
JP (2) | JP6383667B2 (ja) |
KR (1) | KR101679612B1 (ja) |
CN (2) | CN110339369B (ja) |
AR (1) | AR090281A1 (ja) |
AU (1) | AU2013228144B2 (ja) |
CA (1) | CA2866473A1 (ja) |
HK (1) | HK1201858A1 (ja) |
IN (1) | IN2014DN07956A (ja) |
MX (1) | MX369613B (ja) |
MY (1) | MY165211A (ja) |
PH (1) | PH12014502004A1 (ja) |
RU (1) | RU2639256C2 (ja) |
SG (1) | SG11201405537UA (ja) |
TW (2) | TW201341395A (ja) |
UA (1) | UA114192C2 (ja) |
WO (1) | WO2013133659A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR081755A1 (es) * | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AR090281A1 (es) * | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
CN117065044A (zh) * | 2014-03-31 | 2023-11-17 | 韩美药品株式会社 | 通过使用免疫球蛋白Fc片段连接改善蛋白质和肽的溶解度的方法 |
JP2018516874A (ja) * | 2015-06-04 | 2018-06-28 | アントリアバイオ インコーポレイテッドAntriabio,Inc. | 部位特異的タンパク質コンジュゲートの調製のためのアミンpeg化方法 |
EP3325496B1 (en) | 2015-07-24 | 2024-02-07 | Hanmi Pharm. Co., Ltd. | Method of preparing physiologically active polypeptide conjugate |
DK3328881T3 (da) * | 2015-09-08 | 2019-10-07 | Theripion Inc | Apoa-1 fusionspolypeptider og relaterede sammensætninger og fremgangsmåder |
WO2017052329A1 (en) * | 2015-09-24 | 2017-03-30 | Hanmi Pharm. Co., Ltd. | Protein complex by use of a specific site of an immunoglobulin fragment for linkage |
US20200283492A1 (en) * | 2017-09-29 | 2020-09-10 | Hanmi Pharm Co., Ltd. | Long acting protein complex having an enhanced efficiency |
CN111978390B (zh) * | 2020-08-31 | 2022-10-14 | 上海景泽生物技术有限公司 | 聚乙二醇修饰的rhBNP及其用途 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5110906A (en) | 1986-08-21 | 1992-05-05 | The Trustees Of Columbia University In The City Of New York | Derivatives of soluble T-4 |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
EP1324777A1 (en) | 2000-10-05 | 2003-07-09 | Ares Trading S.A. | Regioselective liquid phase pegylation |
AU2002226897B2 (en) | 2000-12-07 | 2007-10-25 | Eli Lilly And Company | GLP-1 fusion proteins |
US7312192B2 (en) | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
SE526711C2 (sv) | 2003-01-31 | 2005-10-25 | Probi Ab | Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav |
US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
DK2599502T3 (en) | 2003-04-11 | 2017-04-18 | Antriabio Inc | Process for Preparation of Site-Specific Protein Conjugates |
AU2004282984B2 (en) | 2003-11-13 | 2011-07-14 | Hanmi Science Co., Ltd. | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
KR101135244B1 (ko) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
US20080207505A1 (en) | 2005-01-12 | 2008-08-28 | James Kenneth D | Bna Conjugates and Methods of Use |
TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
KR100824505B1 (ko) | 2005-08-16 | 2008-04-22 | 한미약품 주식회사 | 개시 메티오닌 잔기가 제거된 면역글로불린 Fc 영역의대량 생산방법 |
RU2428430C2 (ru) | 2005-08-16 | 2011-09-10 | Ханми Холдингс Ко., Лтд. | СПОСОБ МАССОВОГО ПРОИЗВОДСТВА ОБЛАСТИ Fc ИММУНОГЛОБУЛИНА С УДАЛЕННЫМИ НАЧАЛЬНЫМИ МЕТИОНИНОВЫМИ ОСТАТКАМИ |
WO2008051383A2 (en) * | 2006-10-19 | 2008-05-02 | Amgen Inc. | Use of alcohol co-solvents to improve pegylation reaction yields |
JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
AU2008257923B2 (en) | 2007-05-30 | 2013-03-21 | Genexine, Inc. | Immunoglobulin fusion proteins |
JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
WO2009020093A1 (ja) | 2007-08-09 | 2009-02-12 | Daiichi Sankyo Company, Limited | デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム |
AR072596A1 (es) | 2008-07-23 | 2010-09-08 | Hanmi Pharmaceutical Co Ltd | Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico |
CA2747490C (en) | 2008-12-19 | 2017-02-14 | Indiana University Research And Technology Corporation | Insulin analogs |
ES2587397T3 (es) | 2009-03-20 | 2016-10-24 | Hanmi Science Co., Ltd. | Procedimiento para preparar un conjugado específico de sitio de un polipéptido fisiológicamente activo |
WO2011011073A1 (en) | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1 |
WO2011012850A2 (en) | 2009-07-27 | 2011-02-03 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
US8829163B2 (en) | 2010-01-19 | 2014-09-09 | Hanmi Science Co., Ltd | Liquid formulations for long-acting erythropoietin conjugate |
JP5657698B2 (ja) | 2010-01-19 | 2015-01-21 | ハンミ サイエンス カンパニー リミテッドHanmi Scienceco.,Ltd. | 持続型顆粒球コロニー刺激因子結合体の液剤 |
AR080993A1 (es) | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
US9981017B2 (en) | 2010-04-02 | 2018-05-29 | Hanmi Science Co., Ltd. | Insulin conjugate using an immunoglobulin fragment |
AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
AR081755A1 (es) | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
KR101330868B1 (ko) | 2010-06-08 | 2013-11-18 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
KR101337797B1 (ko) | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
KR101830344B1 (ko) | 2010-10-26 | 2018-02-22 | 한미사이언스 주식회사 | 피브로넥틴 단편 및 면역글로불린 단편의 융합 단백질 및 이의 용도 |
KR101303388B1 (ko) | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
CN103502264A (zh) | 2011-04-04 | 2014-01-08 | 国立大学法人东京医科齿科大学 | Hiv立体结构识别抗体诱导肽 |
UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
SG10201604564XA (en) | 2011-06-10 | 2016-07-28 | Hanmi Science Co Ltd | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
AU2012270366C1 (en) | 2011-06-17 | 2017-07-13 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
EP2753348B1 (en) | 2011-09-05 | 2019-12-11 | Hanmi Science Co., Ltd. | Pharmaceutical compositions comprising an interferon alpha conjugate and gemcitabine for the treatment of cancer |
AU2012319308B2 (en) | 2011-10-06 | 2017-08-31 | Hanmi Science Co., Ltd. | Blood coagulation factor VII and VIIa derivatives, conjugates and complexes comprising the same, and use thereof |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
KR101895047B1 (ko) * | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
AU2013216943B2 (en) | 2012-02-10 | 2018-04-19 | Research Corporation Technologies, Inc. | Fusion proteins comprising immunoglobulin constant domain-derived scaffolds |
AR090281A1 (es) * | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
US10064951B2 (en) | 2012-03-30 | 2018-09-04 | Hanmi Science Co., Ltd. | Liquid formulation of highly concentrated long-acting human growth hormone conjugate |
CN103509118B (zh) | 2012-06-15 | 2016-03-23 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
BR112015001052B8 (pt) | 2012-07-19 | 2022-12-27 | Oxford Nanopore Tech Ltd | Métodos para distinguir um polinucleotídeo alvo,sensor para distinguir um polinucleotídeo alvo, e, uso de um construto |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
US10441665B2 (en) | 2012-07-25 | 2019-10-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long acting insulinotropic peptide conjugate |
AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
KR102311517B1 (ko) | 2012-11-06 | 2021-10-14 | 한미약품 주식회사 | 옥신토모듈린과 면역글로불린 단편을 포함하는 단백질 결합체의 액상 제제 |
NZ710564A (en) * | 2013-02-26 | 2020-06-26 | Hanmi Pharm Ind Co Ltd | Site-specific insulin conjugate |
SG10201907106VA (en) * | 2013-02-26 | 2019-09-27 | Hanmi Pharmaceutical Co Ltd | Novel insulin analog and use thereof |
SG11201506937RA (en) * | 2013-03-05 | 2015-10-29 | Hanmi Pharm Ind Co Ltd | Improved preparation method for high-yield production of physiologically active polypeptide conjugate |
AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
AR096890A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
KR102276304B1 (ko) | 2013-09-27 | 2021-07-14 | 한미약품 주식회사 | 지속형 인간 성장 호르몬 제제 |
TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
KR20150140177A (ko) | 2014-06-05 | 2015-12-15 | 한미약품 주식회사 | 단백질 및 펩타이드의 면역원성을 감소시키는 방법 |
CR20180380A (es) | 2015-12-31 | 2018-12-07 | Hanmi Pharm Ind Co Ltd | Agosnista triple de receptores de glucagón/glp-1/gip |
BR112018077457A2 (pt) | 2016-06-29 | 2019-04-02 | Hanmi Pharm. Co., Ltd. | composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado |
-
2013
- 2013-03-07 AR ARP130100755A patent/AR090281A1/es unknown
- 2013-03-08 IN IN7956DEN2014 patent/IN2014DN07956A/en unknown
- 2013-03-08 MX MX2014010734A patent/MX369613B/es active IP Right Grant
- 2013-03-08 CA CA2866473A patent/CA2866473A1/en not_active Abandoned
- 2013-03-08 CN CN201910479805.1A patent/CN110339369B/zh active Active
- 2013-03-08 CN CN201380023673.2A patent/CN104271604A/zh active Pending
- 2013-03-08 SG SG11201405537UA patent/SG11201405537UA/en unknown
- 2013-03-08 KR KR1020130025344A patent/KR101679612B1/ko active IP Right Grant
- 2013-03-08 EP EP13757904.1A patent/EP2822972A4/en active Pending
- 2013-03-08 AU AU2013228144A patent/AU2013228144B2/en not_active Ceased
- 2013-03-08 JP JP2014560857A patent/JP6383667B2/ja active Active
- 2013-03-08 RU RU2014138621A patent/RU2639256C2/ru active
- 2013-03-08 MY MYPI2014002586A patent/MY165211A/en unknown
- 2013-03-08 TW TW102108193A patent/TW201341395A/zh unknown
- 2013-03-08 UA UAA201410250A patent/UA114192C2/uk unknown
- 2013-03-08 WO PCT/KR2013/001885 patent/WO2013133659A1/en active Application Filing
- 2013-03-08 US US14/383,334 patent/US11168109B2/en active Active
- 2013-03-08 TW TW109115220A patent/TW202033536A/zh unknown
-
2014
- 2014-09-08 PH PH12014502004A patent/PH12014502004A1/en unknown
-
2015
- 2015-03-10 HK HK15102405.8A patent/HK1201858A1/xx unknown
-
2018
- 2018-03-13 JP JP2018044927A patent/JP2018104465A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
UA114192C2 (uk) | 2017-05-10 |
JP2018104465A (ja) | 2018-07-05 |
AR090281A1 (es) | 2014-10-29 |
TW202033536A (zh) | 2020-09-16 |
EP2822972A1 (en) | 2015-01-14 |
SG11201405537UA (en) | 2014-11-27 |
KR20130103447A (ko) | 2013-09-23 |
MX2014010734A (es) | 2014-12-05 |
RU2639256C2 (ru) | 2017-12-20 |
US11168109B2 (en) | 2021-11-09 |
WO2013133659A1 (en) | 2013-09-12 |
MY165211A (en) | 2018-03-05 |
PH12014502004A1 (en) | 2014-11-24 |
JP2015514690A (ja) | 2015-05-21 |
CN110339369B (zh) | 2024-01-23 |
US20150299247A1 (en) | 2015-10-22 |
TW201341395A (zh) | 2013-10-16 |
KR101679612B1 (ko) | 2016-11-25 |
MX369613B (es) | 2019-11-14 |
EP2822972A4 (en) | 2015-12-16 |
JP6383667B2 (ja) | 2018-08-29 |
CA2866473A1 (en) | 2013-09-12 |
CN110339369A (zh) | 2019-10-18 |
CN104271604A (zh) | 2015-01-07 |
RU2014138621A (ru) | 2016-04-27 |
AU2013228144B2 (en) | 2017-08-17 |
AU2013228144A1 (en) | 2014-09-25 |
HK1201858A1 (en) | 2015-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN07956A (ja) | ||
MX2019003693A (es) | Formulaciones de insulina de accion prolongada. | |
NZ630848A (en) | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide | |
AU2013334740A8 (en) | Stable, low viscosity antibody formulation | |
EP4253395A3 (en) | Processes for the preparation of carbohydrate conjugated rna agents | |
IN2014DN09922A (ja) | ||
MY156938A (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
EA201890389A3 (ru) | Композиции конъюгата xten и способы их получения | |
MX2016001023A (es) | Formulaciones que contienen dapagliflozina amorfa. | |
BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
WO2013002580A3 (ko) | 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물 | |
PH12016502430A1 (en) | Method for decreasing immunogenicity of protein and peptide | |
MX2012012941A (es) | Nuevas composiciones oftalmicas. | |
WO2014203275A3 (en) | An improved process for the preparation of apixaban and intermediates thereof | |
WO2013022808A3 (en) | Immunogenic protein conjugates and methods for making and using the same | |
PH12015501952B1 (en) | Improved preparation method for high-yield production of physiologically active polypeptide conjugate | |
RU2012110454A (ru) | Способ получения микрокапсул лекарственных препаратов группы цефалоспоринов в интерфероне | |
WO2012115903A3 (en) | Yeast strain for the production of proteins with modified o-glycosylation | |
MX2019012022A (es) | Produccion en alta pureza de proteinas milti-subunitarias tales como anticuerpos en microbios transformados tal como pichia pastoris. | |
EA201791354A2 (ru) | Препараты производных пиримидиндиона | |
WO2013046233A3 (en) | Process for the preparation of octreotide acetate | |
MD4477B1 (ro) | Procedeu de sinteză a 3-(2-bromo-4,5-dimetoxifenil)propannitrilului şi aplicarea acestuia în sinteza ivabradinei şi a sărurilor sale de adiţie cu un acid farmaceutic acceptabil | |
WO2014039787A3 (en) | Germanium-containing camptothecin analogues | |
IN2013MU02059A (ja) | ||
UA77070U (en) | Compound n-benzyl-3-[5'-(2"-aminothiadiazolyl)diphenylphosphino]succinimide with potential physiological properties |